<code id='A248CDDA90'></code><style id='A248CDDA90'></style>
    • <acronym id='A248CDDA90'></acronym>
      <center id='A248CDDA90'><center id='A248CDDA90'><tfoot id='A248CDDA90'></tfoot></center><abbr id='A248CDDA90'><dir id='A248CDDA90'><tfoot id='A248CDDA90'></tfoot><noframes id='A248CDDA90'>

    • <optgroup id='A248CDDA90'><strike id='A248CDDA90'><sup id='A248CDDA90'></sup></strike><code id='A248CDDA90'></code></optgroup>
        1. <b id='A248CDDA90'><label id='A248CDDA90'><select id='A248CDDA90'><dt id='A248CDDA90'><span id='A248CDDA90'></span></dt></select></label></b><u id='A248CDDA90'></u>
          <i id='A248CDDA90'><strike id='A248CDDA90'><tt id='A248CDDA90'><pre id='A248CDDA90'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:leisure time    - browse:87
          Christine Kao/STAT

          The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

          The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

          advertisement

          In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus